Therefore, CD38-nanobody imaging is a strong candidate for translation into the clinic because of its potential to help diagnose MM at its earlier stages, assess treatment response, detect MM-affected bones without causing bone destruction, and allow for same-day imaging with a higher TBR than daratumumab or other mAb-based imaging probes. Here, CD38 is linked to Miyoshi myopathy.